METHODS FOR ACTIVATING POLYMERIC CARRIERS AND COMPOSITIONS PREPARED THEREFROM FOR USE IN AFFINITY CHROMATOGRAPHY

Abstract: Methods of activating polymeric carriers and of covalently binding organic ligands to such activated polymeric carriers, a novel class of products prepared thereby and the use of such products for separation and purification of organic compounds, particularly those of biochemical interest, are disclosed. In one of its aspects, the invention relates to a method of activating polymeric gels and covalently binding organic ligands containing one or more nucleophilic group such as amino, hydroxyl or sulfhydryl groups to such activated polymeric gels. In another of its aspects, the present invention relates to methods and compositions for purification and recovery of specific organic molecules of biological interest, and in particular proteins such as immunoglobulins, through the use of a non-peptido, Protein A and/or Protein G mimetic ligand (i.e., immunoglobulin-binding ligand) bound to a polymeric gel, and to methods for preparation of such non-peptido, Protein A and/or Protein G mimetic ligands via the activated polymers.

Description: METHODS FOR ACTIVATING POLYMERIC CARRIERS AND COMPOSITIONS PREPARED THEREFROM FOR USE IN AFFINITY CHROMATOGRAPHY This invention relates in its various aspects to methods of activating polymeric carriers and of covalently binding organic ligands to such activated polymeric carriers, to a novel class of products prepared thereby and to the use of such products for separation and purification of organic compounds, particularly those of biochemical interest. In one of its more particular aspects the invention relates to a method of activating polymeric gels and covalently binding organic ligands containing one or more nucleophilic group such as amino, hydroxyl or sulfhydryl groups to such activated polymeric gels. In another of its more particular aspects, the present invention relates to methods and compositions for purification and recovery of specific organic molecules of biological interest, and in particular proteins such as immunoglobulins, through the use of a non-peptido. Protein A and/or Protein G mimetic ligand (i.e., immunoglobulin-binding ligand) bound to a polymeric gel, and to methods for preparation of such non-peptido, Protein A and/or Protein G mimetic ligands. Polymers such as polysaccharides, polyvinyl alcohol and Nylon are widely used as solid supports for immobilizing enzymes and for preparing biospecific affinity matrices. Several methods are known for coupling biologically active ligands to water insoluble carriers. These methods have been used for the covalent immobilization of biologically active materials such as enzymes, antibodies or antigens. Immobilized biologically active materials find use in many different fields of technology. One example thereof is in im unologic determination methods. Another important application is in affinity chromatography, wherein an organic ligand having biospecific affinity to some other organic substance has been bonded to a water insoluble polymeric carrier. Proteins have been bonded to water soluble polymers as well as water insoluble polymers for modifying the properties of the protein. The coupling of the ligand to the carrier is often carried out in such a manner that the carrier is first activated by introducing a reactive group into the carrier, which is then reacted with the desired ligand. One example is the use of cyanogen bromide, CNBr, as an activating agent, which is disclosed in Porath, et al.. "Immobilized Enzymes, Methods in Enzymology", Vol. 44 (Mosbach, K. , Ed.) page 19-45, Academic Press, New York (1976) . The use of CNBr for activating hydroxyl groups of polymeric carriers is the earliest and most widely used method. However, CNBr activation procedures suffer from certain disadvantages, namely, (1) the linkages formed between CNBr activated gels and a ino groups of affinity ligands are labile; (2) the reaction results in the introduction of charged species which interfere with affinity absorption; and (3) CNBr is a noxious. lachrymatory and poisonous chemical which requires special care in its handling. Another method for activating polymeric carriers is the use of organic sulfonyl chlorides, particularly 2,2,2-trifluoroethanesulfonyl chloride (tresyl chloride) . Such activating agents are, however, relatively expensive and are difficult to handle and highly moisture sensitive. Efforts to find other methods for coupling ligands to polymeric carriers resulted in the use of a number of different reagents including triazine trichloride, N-hydroxysuccinimide, 1,1- carbonyldiimidazole, certain pyrimidine derivatives and certain epoxy compounds. A method for preparing covalent chromatographic matrices utilizing a hydroxyl containing polymer which has been activated by reaction with 2-fluoro-l-methylpyridinium toluene-4- sulfonate (FMP) has been described in U.S. Pat. No. 4,582,875. This latter method has been found to be most effective for coupling at a pH close to neutral, for example pH 8-9. In fact no known method has been found for preparing an activated polymeric support capable of effectively coupling a ligand at an acidic pH, for example at a pH less than about 4. Since some ligands must be coupled in the acidic pH range, the need arises for an activating agent which can produce activated polymers effective in the acid range of pH. Pepsin, for example, must be coupled at a pH of below about 4 because it is denatured and loses its enzymatic activity at a higher pH. In addition, the development of compositions useful in the non-covalent binding of organic molecules is of tremendous significance to the chemical and biological arts, particularly when such compositions exhibit any degree of binding selectivity. For example, in spite of the widespread development and use of ion-exchange resins and Protein A or Protein G affinity gels for separation and purification of organic materials of biological interest (such as, in particular, polyclonal and monoclonal antibodies as used in diagnostics, purification and experimental therapeutics) , there remain several disadvantages inherent in these methods. The ion-exchange chromatographic method, due to its lack of specificity, requires in general the use of several columns and gradient elution procedures involving specific detection methods to monitor the process. On the other hand, while Protein A affinity gels are somewhat more specific, they are significantly more expensive than ion-exchange chromatography. Moreover, Protein A gels are unable to bind significant amounts of IgG from rats, goats or chickens. There is also the possibility of immune reactions due to Protein A inadvertently leaked into recovered antibody preparations, which may limit the value of chromatographic methods using Protein A gels for purification of materials with which binding does occur. Finally, immobilized Protein A gels are susceptible to microbial and protease degradation, as well as to other protein denaturing agents. Therefore, it would clearly be desirable to develop a chromatographic support with a synthetic ligand, preferably one of low molecular weight and low cost, which would be capable of selectively and efficiently binding molecules of biological interest, and in particular, of binding antibodies from all species. The development of thiophilic gels by Porath et al. is an effort directed toward this end [see, e.g., Porath J. et al., "A New Kind of 'Thiophilic' Electron-Donor-Acceptor Adsorbent," Makromol. Chem. , Macromol. Symp. 17: 359-71 (1988) and references cited therein] . In thiophilic interaction chromatography, antibody is adsorbed on a thiophilic gel in the presence of high concentrations of neutral water- structure-forming salts. Desorption is achieved by elution with buffer not containing the salts. The partial structure of a thiophilic gel may be illustrated as P -0-CH 2 -CH 2 -CH 2 -S0 2 -CH 2 -CH 2 -S-CH 2 -CH 2 - OH, wherein P represents the polymer backbone. The present invention has as one of its objects the provision of a stable and hydrolysis- resistant coupling product of a polymeric carrier and an organic ligand. Another object of the present invention is to provide such a process which can be conducted under relatively mild conditions in order to avoid any detrimental effect upon reactants such as sensitive biological ligands. Another object of the present invention is to provide a series of activating agents which can be reacted with polymeric carriers to produce an activated polymer capable of being coupled to a wide variety of organic ligands at a wide pH range. Another object of this invention is to provide chromatographic matrices which can be used to bind various biologically active materials both covalently and non-covalently. It is another object of the present invention to provide additional synthetic ligands capable of selectively and efficiently binding materials of interest from a variety of different sources. It is a further object of the present invention to develop materials capable of selective binding of antibodies from all species, including those from rats, goats and chickens heretofore not amenable to treatment using conventional purification methods employing Protein A affinity ligands. It is yet a further object of the present invention to provide synthetic affinity ligands capable of adsorbing organic molecules of interest in general, and peptides such as serum proteins in particular, without the use of high salt concentrations in the adsorption process. It is another object of the present invention to provide materials and processes for isolation and purification of immunoglobulins of various classes and from a variety of species without the use of proteinaceous materials which themselves could lead to contamination of the resulting product. These and other objects are achieved in accordance with one aspect of the present invention by forming a reactive derivative of a polymeric carrier by reacting the polymer with a substituted 2- halopyridine as hereinafter defined and then reacting the activated polymer with a ligand containing one or more nucleophilic groups such as amino, hydroxyl or sulfhydryl group to form a coupled product. The method according to this first aspect of the present invention thus comprises an activation step, wherein a substituted 2-halopyridine is introduced into a polymeric carrier and a coupling step in which an organic ligand is bonded covalently to the polymeric carrier. In accordance with another aspect of the present invention, a novel class of compounds and the use thereof in chromatographic methods for binding various biologically active materials non-covalently are disclosed. In particular, in accordance with this aspect of the present invention, the members of a particular class of novel compounds which may be defined as the reaction product of a polymeric gel with a pyridine base, such as 4-dimethylaminopyridine (DMAP) , and a halogen-substituted pyridine, such as 3,5-dichloro-2,4,6-trifluoropyridine (DCTFP) , which reaction product may in turn optionally be reacted with other specified low-molecular-weight compounds or with a source of hydroxide ions, are employed for selective and efficient binding of proteins and other organic materials of interest non-covalently to a degree comparable or superior to the heretofore preferred natural affinity ligands, such as Protein A gels. In particular, it has now been determined that in accordance with one embodiment of this aspect of the present invention, subsequent treatment of the reaction product of a Sepharose gel, DMAP and DCTFP with ethylene glycol leads to the formation of a product (hereinafter, "O-gel") which may be employed to achieve purification and recovery of proteins such as serum albumin and immunoglobulins of various classes from crude sources, such as serum samples from various species. Pursuant to this aspect of the present invention, attempts at elucidation of the structure of these compounds and exploitation of their exceptional utility in separation and purification of organic molecules, and in particular in the recovery of specific proteins in relatively pure form even from crude sources, such as serum samples, are described. The invention in its various aspects may be better understood with reference to the accompanying drawings, in which: Fig. 1 illustrates a provisional assessment of the structure of the compounds of the present invention based on available information as to composition and a proposed reaction pathway for formation thereof; Fig. 2 is a chromatogram of the eluent recovered after treatment of diluted human serum in an O-gel column; Fig. 3 illustrates specific sandwich ELISA patterns of human serum after chromatography on O-gel; Fig. 4 illustrates the results of SDS- gradient polyacrylamide gel electrophoresis on fractions of human serum recovered by elution from an O-gel column; Fig. 5 illustrates the elution pattern of mouse serum (A) and rabbit serum (B) obtained by chromatography on O-gel; Fig. 6 illustrates SDS-gradient polyacrylamide gel electrophoresis of mouse (A) and rabbit (B) sera; Fig. 7 illustrates SDS-gradient polyacrylamide gel electrophoresis of fractions recovered by O-gel chromatography of a mixture of bovine serum albumin and IgG; Fig. 8 illustrates SDS-gradient polyacrylamide gel electrophoresis of fractions recovered by O-gel chromatography of a mixture of chicken serum albumin and IgG; Fig. 9 illustrates SDS-gradient polyacrylamide gel electrophoresis of fractions recovered by O-gel chromatography of a mixture of goat serum albumin and IgG; Fig. 10 illustrates SDS-gradient polyacrylamide gel electrophoresis of fractions recovered by O-gel chromatography of a mixture of mouse serum albumin and IgG; Fig. 11 illustrates SDS-gradient polyacrylamide gel electrophoresis of fractions recovered by O-gel chromatography of a mixture of pig serum albumin and IgG; Fig. 12 illustrates SDS-gradient polyacrylamide gel electrophoresis of fractions recovered by O-gel chromatography of a mixture of rabbit serum albumin and IgG; Fig. 13 illustrates SDS-gradient polyacrylamide gel electrophoresis of fractions recovered by O-gel chromatography of a mixture of rat serum albumin and IgG; Fig. 14 is a chromatogram of the eluent recovered after treatment of diluted goat serum with DCTFP-DMAP activated, hydroxide treated gel; Fig. 15 is a chromatogram of the eluent recovered after treatment of diluted rabbit serum with DCTFP-DMAP activated, glycine treated gel; Fig. 16 is a chromatogram of the eluent recovered after treatment of diluted mouse serum with DCTFP-DMAP activated, glycine treated gel; Fig. 17 is a chromatogram of the eluent recovered after treatment of diluted rabbit serum with DCTFP-DMAP activated, ethylene diamine treated gel; and Fig. 18 is an elution curve illustrating the affinity chromatography of IgG from human serum using Protein A bound to pentafluoropyridine (PFP) activated Sepharose CL- 4B as the affinity matrix. Pursuant to the present invention in all its various aspects, the polymeric carrier can be a water insoluble or water soluble polymeric substance. Except as indicated below, the choice of the carrier is not critical for carrying out the process of the present invention. In principle, any type of carrier can be used which has a polymeric nature and contains at least one nucleophilic group such as a hydroxyl, a ino or sulfhydryl group bonded to a carbon atom which is available for activation and coupling. The carrier is chosen with regard to the requirements in the individual situation, primarily with regard to the type of ligand to be coupled and the intended use of the coupling product. The carrier may be comprised of natural, semi-synthetic or synthetic polymeric materials containing nucleophilic groups. Examples of important natural and semi-synthetic carrier materials are polysaccharide containing materials, for example, cellulose, agarose, dextran and cross-linked products thereof. Examples of synthetic carriers are poly(ethylene glycol) , poly(vinyl alcohol), poly(hydroxyethyl methacrylate) , nylon and the like. It is, of course, also possible to use carriers such as inorganic supports which do not normally contain hydroxyl groups but which, by suitable treatment, can be provided with such groups. An example is silica particles, to the surface of which have been bonded groups containing at least one nucleophilic group. Carriers may be used in the form of various solids, such as gels, beads, fibers, fabrics or membranes or in the form of a soluble polymer. The substituted 2-halopyridines which can be used as activating agents in the activation process according to a first aspect of this invention are derivatives of 2-halopyridines in which at least one of the ring positions of the 2-halopyridine is substituted with an electron withdrawing group. The substituted 2-halopyridine can be represented by means of the structural formula A: wherein X is F, Cl or Br, Y is F, Cl, Br, N0 2 , CH 3 , or CF 3 and n is 1 to 4. Where n is greater than 1, the substituents designated by Y may be the same or different. At least one of the substituents designated by Y must be an electron withdrawing group. Typical compounds include pentafluoropyridine (PFP) , 3,5-dichloro-2,4,6- trifluoropyridine (DCTFP), 3,5-dinitro-2- chloropyridine (CDNP) , 2,3,5-trichloropyridine (TCP), 2,6-difluoropyridine (DFP) , 2-chloro-5- trifluoromethylpyridine (CTFMP) , 2,3,5,6-tetrafluoro- 4-methylpyridine (TFMP) and 2,3,5,6- tetrafluoropyridine (TFP) . The activation of nucleophile containing polymeric carriers can be carried out in the presence of a slight excess of a tertiary amine such as triethylamine, tributyla ine or 4- dimethylaminopyridine (DMAP) in a polar organic solvent such as acetone, dimethylformamide (DMF) , acetonitrile or tetrahydrofuran (THF) . The substituted 2-halopyridines react with the polymeric carrier under a wide range of conditions; for example, the reaction may be carried out at a temperature of about 0 β to about 90" C, preferably under ambient conditions of temperature such as about 22° to 35" C, over a period of time of about 0.1 to about 20 hours. preferably about 0.1 to 2 hours, at atmospheric or slightly elevated pressure. The resulting activated polymers, which react readily with primary or secondary amino, hydroxyl or sulfhydryl' groups of various organic ligands, were found to be stable for at least four months when stored at 4°C in acetone. The activated polymeric carrier can also be stored in dilute mineral acids such as 2 mM phosphoric acid, or in dry form, if desired. The coupling method of this first aspect of the present invention is generally applicable to organic ligands containing the indicated amino, hydroxyl or sulfhydryl groups. Salts of sulfhydryl group containing compounds such as Na salts thereof are likewise useful for this purpose. In general, the product selected for coupling should be a nucleophile, so that the coupling reaction can be carried out smoothly. Thus, the ligand may contain any aliphatic, aromatic, heterocyclic, or heteroaromatic radical or any radical which is a combination of the foregoing, so long as the resulting ligand will have functional groups available for coupling. One type of ligand of special interest includes biologically active ligands, for example, proteins, enzymes, antibodies, antigens, amino acids, nucleic acids, thiol compounds, cofactors, haptens and many other types of biologically active ligands which can be bound covalently to the activated polymeric carrier and used, for example, for affinity chromatographic purposes or in immunoassays or in biocatalysis. Another type of useful ligand is a low molecular weight nucleophilic compound which can be bound covalently to the activated polymeric carrier and then used for the reversible immobilization of various biologically active compounds via non-covalent interaction. 2-Mercaptoethanol, ethylene glycol, and ethanolamine, for example, can be used to form gels which will bind to proteins non-covalently. Such binding can be achieved under relatively low salt conditions such as 0.15 M NaCl in 0.02 M to 0.05 M sodium phosphate, pH 7.4 or 0.05 M sodium bicarbonate, pH 8.5. These gels can also be used for the enrichment of the specific radioactivity of labeled proteins, for example 1-125 labeled bovine serum albumin (BSA) or human IgG. Reacting the activated polymeric carrier with hydroxide ions such as by treatment with a base, for example NaOH or NaHC0 3 or Na 2 C0 3 also produces gels which can be used to bind various biologically active materials non-covalently. Coupling of the ligand to the activated polymeric carrier can be accomplished under varying conditions of temperature and pH and can be performed in aqueous reaction media as well as in polar organic solvents. Reaction conditions are not critical for either the activation step or the coupling step and are primarily chosen with regard to the sensitivity of the reactant and to practical considerations of convenience. Mild reaction conditions are preferred. It is, for example, often suitable to work at ambient temperatures and pressures. The pH at which the coupling reaction is carried out can range from an acidic pH, for example, a pH less than about 4, to an alkaline pH, for example, a pH of about 10. Unreacted activated groups remaining after coupling, which might impede further utilization of the coupled polymer, can be deactivated by suspending the coupled polymer in 0.2 M Tris-HCl, pH 9 or in 0.IM NaOH, at room temperature, for several hours. Other nucleophiles such as glycine or lysine can also be used for this purpose. An outstanding advantage of the activation method according to this first aspect oϊ the present invention is that of providing chromatographic matrices characterized by a very stable chemical linkage between the affinity ligand and the solid matrix to which it is bound. If such stable chemical linkage is not formed, loss of the affinity ligand from the matrix can result in contamination of the purified material obtained by use of such chromatographic matrix and shortening of the useful life of the matrix. The method of this first aspect of the invention results in minimal detachment of affinity ligands even upon subsequent exposure to basic and nucleophilic buffers and thus provides superior chromatographic matrices. Another advantage is the realization of significantly greater ligand binding capacity of the activated polymeric carrier than in the case of methods presently available. In another of its particular aspects, the present invention is directed to a novel class of products, and to the use thereof as highly selective and efficient chromatographic adsorbents for the recovery and purification of organic materials, particularly those of biological interest. This class of materials may be employed, " for example, in the separation and purification of immunoglobulins of various classes and from various species, permitting the recovery of the immunoglobulins in substantially purified form directly from crude sources, such as dilute serum samples. In accordance with this second aspect of the present invention, this novel class of compounds comprises polymeric carriers with synthetic affinity ligands bound thereto. These compounds may be described as the reaction products of a nucleophile- containing polymeric carrier, a halogen-substituted pyridine (as hereinafter defined) and a pyridine base (as hereinafter defined) . While the absolute structure of these novel compounds has not been resolved with certainty, it is believed that the compounds are represented by either of the general formulas 1(a) or 1(b) A is O, S or NR, in which R is hydrogen or optionally substituted alkyl, aryl or aralkyl; each X is independently selected from the group consisting of halogen, trihalomethyl and nitro; each Y is independently selected from the group consisting of halogen, hydroxyl, amino and -A^, in which A 1 is O, S or NR g , R A is optionally substituted alkyl, aryl, or aralkyl, and R g is hydrogen or optionally substituted alkyl, aryl or aralkyl, with the proviso that at least one Y in Formula I(_a) or Y in Formula 1(b) is not halogen; each of X, is hydrogen or optionally substituted alkyl, aryl or aralkyl; at least one Y, is hydrogen and the other is hydrogen or optionally substituted alkyl, aryl or aralkyl; R., is hydrogen, optionally substituted alkyl, aryl or aralkyl, or -N ^, in which R 2 and R 3 are the same or different and are optionally substituted alkyl, aryl or aralkyl-; and |- is a polymer. In the context of this application, "alkyl" refers to straight- or branched-ch in alkyl of one to about 20 carbon atoms, preferably from one to about eight carbon atoms, as well as aliphatic cyclic substituents (such as cyclopentyl and cyclohexyl) ; "aryl" refers to aromatic hydrocarbon (such as benzyl, naphthyl, anthracyl, etc.) and heterocyclic (such as furanyl, thiophenyl, pyridyl, etc. ) substituents; and "aralkyl" refers to benzyl, alk lphenyl, alkylnaphthyl, etc. By "optionally substituted" herein is meant that the subject alkyl, aryl or aralkyl group may bear one or more substituents which are the same or different and are substantially inert to an addition or nucleophilic substitution reaction with the hydroxyl, thiol or primary or secondary amino groups of the compounds of biological interest to be recovered by affinity chromatographic methods using the product of Formula 1(a) or 1(b) under the specified chromatography conditions. In general, undesired side-reactions with the molecules to be recovered are likely to occur only with highly reactive disulfide or thiol groups and halogens (generally, as are found in structures where there are substantial electronic and/or steric factors contributing to reactivity) or "activated" hydroxyl groups (for example, FMP-treated hydroxyl groups as taught in U.S. Patent 4,582,875). Accordingly, suitable substituents for the subject alkyl, aryl or aralkyl groups include hydroxyl and hydroxyalkyl; primary, secondary or tertiary amino and alkylamino; sulfonyl and alkylsulfonyl; carboxyl and carboxylate; alkylcarbonyl; acyl and carboxyalkyl; nitro and nitroalkyl; amido and alkylamido; and thioalkyl. The compounds of this aspect • of the invention, the structures of which are believed to be represented by one of the general formulas 1(a) or 1(b), may be prepared by a number of different synthetic routes. According to a first such route, a suitable polymeric carrier is reacted with a halogen- substituted pyridine and a pyridine base, such as 4- dimethylaminopyridine (DMAP) . In an alternative route of synthesis, the halogen-substituted pyridine is first reacted with the pyridine base to form an intermediate, some of which are themselves novel compounds, and the intermediate in turn is reacted with the polymeric carrier to provide the compounds of the invention. It has now been determined that, in contrast to the type of activation which occurs in the presence of other bases and/or with substituted halopyridine reactants of the type specified in accordance with a first aspect of the present invention, a different reaction mechanism appears to be involved in the reaction of a nucleophile containing polymeric carrier with a pyridine base and a halogen-substituted pyridine of the types specified pursuant to a second aspect of the present invention. Indeed, when the reactants are chosen in accordance with this second aspect of the present invention, it is believed that both the pyridine base and the halogen-substituted pyridine are incorporated into the final product. Moreover, it is further believed that the proposed structure of general formula 1(a) may be formed by an opening of the pyridine base ring during the course of the synthesis of the compounds of the instant invention, resulting in the formation of an extended conjugated system. Such an extended conjugated system is also present in alternative proposed structure 1(b). As a consequence, the novel compounds of this second aspect of the present invention are found to be strongly fluorescent, whereas neither the individual reactants nor the products of an activation/coupling reaction scheme in accordance with a first aspect of the present invention exhibit in general any such fluorescence. While it has not yet been determined with certainty the actual mechanism whereby the compounds of this second aspect of the invention are formed, and indeed whether the compounds do in fact have the structure proposed in general formula 1(a) or 1(b), it is believed that formation of the compounds of this second aspect of the present invention proceeds in accordance with a reaction pathway as illustrated in Fig. 1. This proposed reaction pathway has been derived with respect to general formula 1(a) in accordance with the study of Chambers et al. as to the mechanisms involved in the reaction of pentachloropyridine with an excess of pyridine at 50° C to form a monopyridinium salt, followed by ring opening of the salt with an excess of dimethylamine in water at room temperature [Chambers, R.D. et al. , "Pyridinium salts of halogenated heterocyclic compounds," Chem. Ind. (London) 89 (1975)]. The halogen-substituted pyridines which can be used in the preparation of the chromatographic adsorbents of this second aspect of the present invention from suitable polymeric carriers comprise a class of pyridine compounds defined differently from the 2-halopyridines contemplated for general use in activation of nucleophile-containing polymers in accordance with a first aspect of the present invention. For purposes of activation and coupling, any 2-halopyridine may be employed in which at least one of the ring positions of the 2-halopyridine is substituted with an electron withdrawing group. Pursuant to this second aspect of the present invention, however, there is required a halogen- substituted pyridine represented by means of the general formula II: wherein each X 2 is independently selected from the group consisting of halogen, trihalomethyl and nitro; at least one Y 2 is halogen and the other Y 2 is selected from the group consisting of halogen and -A^, in which A, is O, S or NR g , R A is optionally substituted alkyl, aryl, or aralkyl, and R g is optionally substituted alkyl, aryl or aralkyl; and Z 2 is a suitable leaving group (generally, halogen such as F or Cl) . Typical halogen-substituted pyridine compounds for use in accordance with this second aspect of the present invention include pentafluoropyridine (PFP) , 3,5-dichloro-2,4,6- trifluoropyridine (DCTFP) , and pentachloropyridine (PCP) . Whereas the activation of nucleophile- containing polymeric carriers in accordance with a first aspect of the present invention is carried out in the presence of a slight excess of any tertiary a ine exhibiting the desired basic activity (such as triethylamine, tributylamine or 4-dimethylamino- pyridine) in a polar organic solvent such as acetone, dimethylformamide (DMF) , acetonitrile or tetrahydrofuran (THF) , pursuant to this second aspect of the present invention the pyridine base is itself a reactant involved in the formation of the novel chromatographic adsorbents and is incorporated into the structure of the proposed final product. Generally, the pyridine base for use in the formation of the products of this second aspect of the invention is of the general formula III: wherein each of X., is hydrogen or optionally substituted alkyl, aryl or aralkyl; at least one Y, is hydrogen and the other is hydrogen or optionally substituted alkyl, aryl or aralkyl; and R, is hydrogen, optionally-substituted alkyl, aryl or aralkyl, or -NR 2 R 3 in which R 2 and R 3 are the same or different and are optionally- substituted alkyl, aryl or aralkyl. Pursuant to a first synthetic route for preparation of compounds of this second aspect of the invention, the pyridine base, the polymeric carrier and the halogen-substituted pyridine are reacted together in a so-called one pot reaction in a suitable organic solvent, preferably a polar organic solvent. A wide range of temperature and pressure conditions are suitable. In general, the reaction may be carried out at a temperature of about 0° to about 90°, preferably at an ambient temperature on the order of about 22° to 35° C, over a time period of about 0.1 to about 20 hours, preferably about 0.1 to about 2 hours, at atmospheric or slightly elevated pressure. Suitable solvents include dimethylformamide (DMF) , acetonitrile and tetrahydrofuran (THF) . The resulting products are believed to have a structure as : wherein t e substituents are as previous y defined. These compounds (depending upon the substitution pattern) are either effective as chromatographic adsorbents per se and/or serve as precursors to such adsorbents (e.g., upon further reaction with a suitable base or low molecular weight compounds. Pursuant to an alternative synthetic route, the compounds of general formulas II and III are first coupled together under reaction conditions similar to those described above for the one-pot reaction and in a suitable organic solvent to _form an intermediate of general formula V: wherein Z is a suitable counterion (for example, halogen) and the remaining substituents are as previously defined. In this case, a particularly suitable solvent is chloroform, as the intermediate will in general precipitate out of solution. This intermediate in turn is then reacted in a suitable organic solvent under basic conditions (i.e., in DMF in the presence of tributylamine) with the polymeric carrier to form a compound of general formula IV(a) or IV(b) . This reaction may also be carried out over a fairly broad range of temperatures and times (e.g., a temperature of about 0° to about 90°, preferably at an ambient temperature on the order of about 22° to 35° C, over a time period of about 0.1 to about 20 hours, preferably about 0.1 to about 2 hours, at atmospheric or slightly elevated pressure) . In accordance with this second aspect of the present invention, the reaction product of general formula IV(a) or IV(b) , i.e., the reaction product of the polymeric carrier with an appropriate halogen- substituted pyridine and pyridine base, may in turn be reacted with a base or a low molecular weight nucleophilic compound, in particular in those cases where at least one Y 2 in Formula IV(a) or Y 2 in Formula IV(b) is halogen. Thus, it is contemplated according to the present invention to replace a given Y 2 substituent which itself may or may not fall within the definition of Y with a different substituent also falling within the definition of Y, so as to provide a final product having a different (e.g., selective or enhanced) binding affinity for a given material or group thereof. Preparation of the desired product may be indicated by the presence of fluorescence in the recovered gel in aqueous and/or other polar solvent solution. Suitable low molecular weight compounds for preparation of the desired chromatographic adsorbents are of the general formula VI: R 6 - B - R 7 wherein B is an optionally-substituted alkyl, aryl or aralkyl moiety of 2 to about 10 carbon atoms; and each of R 6 and R 7 is -OH, -SH or -NR g R p , in which each of R 8 and R g is hydrogen or optionally-substituted alkyl, aryl or aralkyl. Examples of suitable low-molecular- weight compounds which can be used to form gels which bind proteins and other organic molecules of interest non-covalently include 2-mercaptoethanol, ethylene glycol, and ethanolamine. Other suitable low molecular weight compounds include non-vicinal diols and glycols, alkylenediamines, dithiothreitol and amino acids, such as glycine. Reacting an intermediate of general formula IV wherein Y 2 is, e.g., halogen with hydroxide ions, such as by treatment with a base (for example, NaOH, NaHC0 3 or Na 2 C0 3 ) also produces gels which can be used to bind reversibly various biologically active materials non-covalently. Reaction of the low molecular weight molecules with the intermediate of general formula IV can be accomplished under varying conditions of temperature and pH and can be performed in aqueous reaction media as well as in organic solvents. In general, any solvent which is inert to the reactants (i.e., any non-nucleophilic solvent) may be employed. Temperatures on the order of about 0° to about 100° C and times of about 10 minutes to about 20 hours are generally suitable. Reaction conditions are not critical and are primarily chosen with regard to the sensitivity of the reactant and to practical considerations of convenience. Mild reaction conditions are preferred. It is, for example, often suitable to work at ambient temperatures and pressures. The pH at which the reactions are carried out can range from an acidic pH, for example, a pH less than about 4, to an alkaline pH, for example, a pH of about 10. The chromatographic adsorbents prepared in accordance with this second aspect of the present invention are characterized by a very stable chemical linkage between the affinity ligand and the solid matrix to which it is bound. If such stable chemical linkage is not formed, loss of the affinity ligand from the matrix could result in contamination of the purified material obtained by use of such chromatographic matrix and shortening of the useful life of the matrix. The described reaction schemes result in a minimal probability of detachment of affinity ligands even upon subsequent exposure to basic and nucleophilic buffers, and thus provides superior chromatographic adsorbents. Another advantage is believed to be the realization of significantly greater affinity binding capacity of the chromatographic adsorbent than is the case with many other heretofore known adsorbents, including the preferred proteinaceous adsorbents in current use such as bound Protein A gels. A primary advantage of the inventive compounds, of course, is that highly efficient and selective binding of organic molecules of interest, in particular proteins, may be achieved using a synthetic affinity ligand of relatively low molecular weight (on the order of less than about 1000) , rather than a proteinaceous ligand as heretofore preferred, such as Protein A (molecular weight 42,000) . The novel gels of this second aspect of the present invention are particularly useful for non- covalent binding of biologically active ligands, for example, proteins, enzymes, antibodies antigens, amino acids, nucleic acids, thiol compounds, cofactors, haptens and many other types of biologically active ligands. Of particular interest is the extraordinary affinity of the reaction product of either Sepharose C1-4B or Fractogel TSK HW 75 F activated by 3,5-dichloro-2,4,6-trifluoropyridine and 4-dimethylaminopyridine with ethylene glycol (the "O- gel") for IgG from a variety of different species, including rats, goats and chickens (for which Protein A does not show significant affinity) . Such binding can be achieved under relatively low salt conditions such as 0.02 M sodium phosphate (pH 7.5), 0.15 M NaCl in 0.02 M to 0.05 M sodium phosphate (pH 7.4) or 0.05 M sodium bicarbonate (pH 8.5). These gels can also be used for the enrichment of the specific radioactivity of labeled proteins, for example 1-125 labeled bovine serum albumin (BSA) or human IgG. Based on detailed analysis of results using an exemplary compound in accordance with the instant invention (i.e., the aforementioned O-gel) for the recovery of particular proteins from diluted serum samples obtained from various species, it has been determined that the gels of this second aspect of the present invention possess several unique attributes which distinguish them from all known chromatographic adsorbents, and in particular from the thiophilic gels of Porath et al. First, the binding of proteins to 0- gel does not require the presence of a high concentration of water-structure-forming salts, as is the case with the thiophilic gels. In fact, almost all the serum proteins applied to the O-gel in the absence of high salt concentrations were adsorbed, and some albumin from the serum was actually desorbed by the presence of high salt. In this respect, the chromatographic adsorbent of this second aspect of the instant invention may also be distinguished from bound Protein A gels, with respect to which there is an increase in binding observed using elevated concentrations of a buffer comprising a monovalent cation and a polyvalent anion over a specified pH range (as disclosed in U.S. Patent 4,801,687), and allegedly observed using high concentrations of any inorganic salt at a pH above 7.5 (cf. U.S. Patent 4,704,366) . Further, the desorption of bound IgG from 0- gel is achieved by decreasing the pH of the eluting solution. According to the method of Porath et al., desorption is achieved through decreases in salt concentration. Perhaps as a consequence of this difference, the albumin fraction recovered using 0- gel is highly pure and almost entirely free of other protein contaminants, in contrast to product as recovered using the thiophilic gel. Finally, the chemistry of the non-covalent binding according to this second aspect of the present invention is clearly different from that of the thiophilic gels. Thiophilic gels require the presence of sulfone and thioether functional groups for binding. In contrast, there is no participation of any sulfur element in the O-gels; moreover, even in those gels wherein sulfur-containing ligands are employed, the nature of the interaction between the affinity ligand and the molecule bound thereto is clearly different in nature from what occurs in the case of thiophilic gels. The details of the mechanism of protein adsorption to the compounds of the present invention, such as O-gel, are currently not known. The unique adsorption characteristics of the O-gel and its analogues, however, may be associated with the formation of a highly conjugated system, as evidenced by the strong fluorescence of O-gel in aqueous solution. In any event, the high capacity for adsorption of proteins at low ionic strength and the high binding selectivity of the gel are both contrary to commonly known, non-selective processes of hydrophobic interaction chromatography. Moreover, continuous adsorption of proteins at 0.5 M salt concentrations is not consistent with ion-exchange chromatography. The absence of any sulfur-containing group in O-gel clearly disqualifies the process as thiophilic. Thus, based on the available information, it appears that the adsorption of proteins and other organic molecules of biological interest to compounds of this second aspect of the instant invention, such as O-gel, involves a novel protein adsorption process heretofore neither demonstrated nor recognized. The invention will be better understood by reference to the following examples which are intended for purposes of illustration and are not to be construed as in any way limiting the scope of the present invention, which is defined in the claims appended hereto. Example 1 Reaction of SEPHAROSE CL-4B with Pentafluoropyridine fPFP) and 4-Dimethylaminopyridine fDMAP) SEPHAROSE CL-4B, a cross-linked agarose gel from Pharmacia Fine Chemicals, Uppsala, Sweden (100 ml) was washed five times with 100 ml distilled water each time. The washed gel was suspended in 100 ml distilled water in a 2 L beaker mounted on a shaker rotating at 100 rpm. To the gel suspension was added 1 L acetone over 30 minutes duration. The gel was filtered and resuspended in 1 L dry acetone and was tumbled at room temperature for 15 minutes after filtering. The gel was then suspended in 200 ml dry acetone. To 10 ml acetone washed gel, in a polypropylene bottle was added 30 ml dry DMF. The suspension was tumbled for 5 minutes. After filtering, the gel was suspended in 10 ml dry DMF containing 5.5 millimoles DMAP. To the gel suspension was further added 25 ml DMF containing 5 millimoles of PFP. After tumbling at room temperature for 2 hours, the gel was washed with 100 ml DMF and twice with 100 ml acetone each time. The washed, activated gel was stored in 30 ml acetone at 4 β C; under these conditions, it can remain stable for several weeks. Example 2 Reaction of SEPHAROSE CL-4B with 3.5-Dichloro-2.4.6-trifluoropyridine (DCTFP) The procedure of Example 1 was repeated using 3,5-dichloro-2,4,6-trifluoropyridine (DCTFP). Example 3 Reaction of FRACTOGEL TSK HW 75F with 3.5-Dinitro-2-chloropyridine fCDNP) The procedure of Example 1 was repeated using FRACTOGEL TSK HW 75F, a porous, semi-rigid spherical gel synthesized from hydrophilic vinyl polymer and composed exclusively of C,H and 0 atoms, supplied by E. Merck, Darmstadt, Geirmany as the matrix and 3,5-dinitro-2-chloropyridine (CDNP) . Other 2-halopyridines used were 2,3,5- trichloropyridine (TCP); 2,6-difluoropyridine (DFP) ; 2-chloro-5-trifluoromethylpyridine (CTFMP) ; 2,3,5,6- tetrafluoro-4-methylpyridine (TFMP) and 2,3,5,6- tetrafluoropyridine (TFP) . Example 4 Reaction of Paper with 3,5-Dichloro- 2.4.6-trifluoropyridine (DCTFP) in Dimethylformamide (DMF) Twenty pieces of Schleicher & Schuell 589 WH filter paper (5 cm X 6.5 cm) were immersed in 100 ml dry DMF for 10 minutes. The papers were removed and placed in 100 ml dry DMF containing 10 millimoles DMAP. The paper suspension was placed on a shaker rotating at 100 rpm for 5 minutes at room temperature. To this suspension was added 10 millimoles DCTFP in 100 ml dry DMF and the shaking was continued. At various time intervals (0.5, 5, 10, 15, 30, 60, 90 minutes) , one piece of the paper was removed, blotted dry on several layers of paper towel, placed in 100 ml dry DMF and shaken for 5 minutes. This washing step was repeated once more with dry acetone instead of dry DMF. Finally the paper was air-dried in a fume hood. Example 5 Reaction of Nylon Membrane with 3.5-Dichloro-2.4.6-trifluoropyridine (DCTFP) Ten Nylon membrane disks (MicronSep Magna Nylon 66 Type 5 from Fisher Scientific Co.) were suspended in 25 ml DMF containing 13.75 millimoles DMAP. To this suspension was added 62.5 ml DMF containing 12.5 millimoles DCTFP. The membrane suspension was rotated at 150 rpm. at room temperature for 2 hours. Then the membranes were washed successively with 200 ml DMF and 200 ml acetone. The washed membranes were air dried at room temperature and stored dessicated at 4 β C. Example 6 Coupling of Bovine Serum Albumin fBSA) to Activated Gel One volume of activated gel prepared as in Examples 1 to 3 was washed with 10 volumes distilled water. Immediately after washing, one volume of activated gel was added to one to two volumes BSA and the suspension was tumbled at room temperature for 20 hours. The unreacted activated groups were deactivated by reacting the gel with equal volume 0.2 M ethanolamine in 0.1 M Tris, pH 9 at room temperature for 8 hours. The BSA solution was prepared in buffer with no amino or other nucleophilic groups. Acetate buffer was used for pH 1-4; phosphate buffer was used for pH 5-7 and bicarbonate buffer was used for pH 8- 10. The amounts of BSA coupled at various pH's using various activators and gels are shown in Table 1. TABLE 1 BSA Coupled (mg BSA/ml gel) Activator Gel Coupling pH 4 8 Pentafluoro¬ Fractogel 8 20.6 pyridine Sepharose b 4.8 3,5-Dichloro- Fractogel 30.0 2,4,6-trifluoro¬ pyridine Sepharose 32.8 3,5-Dinitro- Fractogel 14.7 2-chloro- pyridine Sepharose 0.5 2,3,5-Tri- Sepharose 0.3 chloro- pyridine 2,6-Difluoro¬ Fractogel 0.6 pyridine Sepharose 2-Chloro-5- Sepharose trifluoromethyl- pyridine 2,3,5,6-Tetra- Sephacryl c 0.4 fluoro-4-methyl- pyridine 2,3,5,6-Tetra- Sepharose 0.9 fluoropyridine 3 Fractogel TSK HW 75F, trademark of E. Merck. Sepharose C1-4B, trademark of Pharmacia. c Sephacryl S-300 a copolymer of dextran and acrylamide, trademark of Pharmacia. Example 7 Coupling; of Bovine Serum Albumin (BSA) to Activated Paper Disks of activated paper (diameter: 1.3 cm) prepared according to the method of Example 4 were each placed in 1 ml 1-125 labeled BSA (40 mg/ml in 0.5 M sodium bicarbonate, pH 8.5) in a test tube. The tubes were tumbled at room temperature for 20 hours. Each disk was washed twice with 10 ml of each of the following solutions: distilled water, 1 M NaCl, 1.5 M KSCN, 8 M urea, phosphate buffered saline (PBS) , 10% sodium dodecyl sulfate (SDS) and distilled water. The radioactivity of each disk was measured and the quantity of BSA bound to each disk was determined. It was found that 6 mg BSA could be bound to 1 square centimeter of paper after 30 minutes activation. Very little of the bound BSA could be eluted by treating the paper with chaotropic solutions such as 15 M KSCN or 8 M urea and a strong detergent such as 10% SDS solution. Example 8 Binding of 1-125 Labeled Bovine Serum Albumin CBSA) to DCTFP-activated Nylon Membrane DCTFP-activated Nylon membrane (1 cm. X 1 cm.) prepared according to the procedure of Example 5 was suspended in 2 ml 1-125 labeled BSA (40 mg/ml) and tumbled at room temperature for 20 hours. The membrane was successively washed with 8 ml PBS, 1 M NaCl, 1.5 M KSCN, 8 M urea, 10% SDS and distilled water. It was found that 2.80 mg 1-125 BSA was bound per square centimeter of membrane compared to 0.85 mg/cm 2 for a control unactivated membrane. Example 9 Coupling of β-Galactosidase to DCTFP-Activated SEPHAROSE CL-4B DCTFP activated SEPHAROSE CL-4B gel (2.5 ml) was washed with 25 ml distilled water. The filtered gel was added to 1 ml β-galactosidase solution (5 mg enzyme in 1 ml PBS) . The gel suspension was tumbled at room temperature for 2 hours. The gel was washed twice with 5 ml PBS, four times with 5 ml PBS with 0.5 ml NaCl and two times with 5 ml PBS. The immobilized enzyme having 14 mg enzyme bound per milliliter of gel with 40% retention of enzyme activity was stored in PBS at 4°C. Example 10 Immobilization of Pepsin to SEPHAROSE CL-4B Activated bv 3.5-Dichloro-2.4.6-trifluoropyridine (DCTFP) Pepsin (70 mg) purified from porcine stomach mucosa with a specific activity of 3100 units per milligram of protein was dissolved in 2 ml 0.1 M sodium acetate, pH 3.4. Then 5 ml of DCTFP-activated SEPHAROSE CL-4B gel was added to the enzyme solution and was allowed to tumble at room temperature for 20 hours. The immobilized pepsin was washed with 50 ml 0.1 M sodium acetate, pH 3.5; 50 ml 0.1 M sodium acetate, pH 3.5, containing 0.5 M NaCl and 50 ml 0.05 M HC1. The immobilized pepsin was then suspended in 50 ml 0.5 M ethanolamine in acetate buffer, pH 3.5 and was tumbled at 4°C for 5 hours. After filtering off the supernatant, the immobilized enzyme was resuspended in 50 ml 0.1 M sodium acetate, pH 3.5 and was tumbled at room temperature for 15 minutes and washed with 50 ml 0.05 M HC1. The immobilized pepsin was stored in 10 ml 0.05 M HC1 with 50% glycerol and 0.1% sodium azide at 4°C. The immobilized pepsin was found to have an activity of 17,635 units per milliliter of gel and contained 6 mg protein per milliliter of gel. Example 11 Coupling of Ribonucleic Acid (RNA) to DCTFP Activated SEPHAROSE CL-4B Gel One volume of DCTFP-activated SEPHAROSE CL- 4B gel was washed with 10 volumes distilled water. Immediately after washing, 0.5 ml activated gel was added to 2 ml solution of tritium labeled calf thymus ribonucleic acid (10 mg H-3 RNA per ml in 0.05 M sodium bicarbonate, pH 8.5) and the suspension was tumbled at room temperature for 20 hours. The gel was successively washed with 8 ml PBS, 1 M NaCl, 8 M urea, 10% sodium dodecyl sulfate and distilled water. The immobilized RNA gel (0.25 ml) was mixed with 4 ml liquid scintillation fluid and then the radioactivity was counted in a β-counter. It was found that 2 mg of RNA was bound to 1 mg gel. Example 12 Preparation of Immobilized Protein A Gel PFP-activated SEPHAROSE CL-4B (5 ml) was suspended in 5 ml Protein A solution containing 10 mg Protein A per ml 0.05 M NaHC0 3 , pH 8.5. The gel suspension was tumbled at room temperature for 24 hours. The gel was washed with 50 ml 0.05 M NaHC0 3 , 50 ml 0.5 M NaCl and 50 ml 0.05 M NaHC0 3 . The washed gel was tumbled in 50 ml 0.1 M ethanolamine in 0.05 M NaHC0 3 , pH 8.5 at room temperature for 5 hours. The immobilized Protein A gel was washed with 25 ml PBS containing 2 M NaCl, 25 ml 1 M glycine, pH 2.8 and 25 ml PBS. Example 13 Preparation of 2-Mercaptoethanol Substituted DCTFP--Activated SEPHAROSE CL-4B Gel DCTFP activated SEPHAROSE CL-4B (10 ml) was washed with 100 ml distilled water and 100 ml 0.1 M sodium bicarbonate, pH 9. The washed gel was suspended in 10% 2-mercaptoethanol in 0.1 M sodium bicarbonate, pH 9 and tumbled end-to-end at room temperature for 24 hours. The gel was washed with 100 ml bicarbonate buffer and then resuspended in 20 ml 0.1 M NaOH and tumbled at room temperature for 14 hours. Finally, the gel was washed sequentially with 100 ml 1 M NaCl, 100 ml distilled water and 100 ml PBS and stored in PBS at 4°C. In the same manner an affinity gel was prepared using ethanolamine or 3-mercaptopriopionic acid in place of the 2-mercaptoethanol. Example 14 Preparation of 2-Mercaptoethanol Substituted PFP Activated Gel The procedure of Example 13 was repeated using PFP activated SEPHAROSE CL-4B as the activated gel. In addition to 2-mercaptoethanol, ethylene glycol and ethanolamine were used as ligands. Example 15 Preparation of Ethylene Glycol Substituted Gel (O-Gel) The procedure of Example 13 was followed, using 1 ml ethylene glycol in place of the 2- mercaptoethanol. After resuspension of the product in 20 ml 0.1 M NaOH and tumbling at room temperature for 14 hours, the product was washed sequentially with 100 ml distilled water, 100 ml 1 M NaCl, 100 ml distilled water and 100 ml PBS. The product was stored in PBS at 4° C when not in use. Example 16 Coupling of Dithiothreitol (DTT) to 3,5-Dichloro- 2.4.6-Trifluoropyridine (DCTFP) Activated SEPHAROSE CL-4B DCTFP-activated SEPHAROSE gel (2 ml) was washed with 20 ml distilled water. The washed gel was suspended in 15 ml 0.1 M DTT in 0.05 M sodium bicarbonate, pH 8.5 and mixed vigorously on a Vortex mixer briefly. The gel suspension was left standing at room temperature for 48 hours. The reacted gel was washed with 20 ml of distilled water, 1 M NaCl, 8 M urea, distilled water and 0.1 M sodium bicarbonate, pH 8.5. The density of thiol group was determined by using Ellman reagent, G.L. Ellman, Arch. Biochem. Biophys. J2, 70 (1959), and was found to be 42-48 micromoles per milliliter of gel. Example 17 Preparation of Iodoacetamide-Blocked Dithiothreitol Substituted Gel The reaction product of Example 16 was washed with distilled water and then suspended in 0.1 M iodoacetamide (0.1 M phosphate buffer, pH 7.0) for 14 hours at room temperature. The gel was washed with distilled water and 0.5 M NaCl solution and stored at 4° C in PBS. Example 18 Preparation of Glvcine Substituted Gel The reaction product of Example 1 (10 ml) was washed with 100 ml distilled water and 100 ml 0.1 M sodium bicarbonate (pH 9) . The washed gel was suspended in 1 M glycine (0.1 M sodium bicarbonate, pH 9) and tumbled end-to-end for 24 hours at room temperature. The gel was washed with 100 ml bicarbonate buffer and then resuspended in 20 ml 0.1 M NaOH. This suspension was tumbled for 14 hours at room temperature. Finally, the gel was washed with 100 ml 1 M NaCl, 100 ml distilled water and 100 ml PBS. The product was stored at 4° C in PBS. Example 19 Preparation of Glutamate and Ethylene Diamine Substituted Gels The reaction product of Example 1 (10 ml) or of Example 2 (10 ml) was washed with 100 ml distilled water and 100 ml 0.1 M sodium bicarbonate (pH 9). The washed gel was suspended in 1 M glutamate (0.1 M sodium bicarbonate, pH 9) and tumbled end-to-end for 24 hours at room temperature. The gel was washed with 100 ml bicarbonate buffer and then resuspended in 20 ml 0.1 M NaOH. This suspension was tumbled for 14 hours at room temperature. Finally, the gel was washed with 100 ml 1 M NaCl, 100 ml distilled water and 100 ml PBS. The product was stored at 4° C in PBS. Following an analogous procedure using 1 M ethylene diamine, the ethylene diamine substituted gel was also prepared. Example 20 Preparation of Hydroxide Ion Treated Gels The procedure of Examples 13 and 14 was repeated except that DCTFP or PFP activated gels were suspended in 0.1 M sodium bicarbonate, pH 9 without addition of an organic ligand. Example 21 Preparation of Adduct of DMAP and DCTFP (Intermediate) One equivalent each of 4- dimethylaminopyridine (DMAP) and 3,5-dichloro-2,4,6- trifluoropyridine (DCTFP) dissolved in chloroform were reacted together at room temperature for about 14 hours and then at -20° C for about 6 hours. Precipitated solids were removed and washed three times with diethyl ether. The product was recrystallized from tetrahydrofuran. The overall yield was approximately 70%. Example 22 Preparation of Ethylene Glycol Substituted Gel via Reaction Product of DMAP-DCTFP Adduct with Sepharose CL-4B Sepharose CL-4B (25 ml) was washed with acetone to remove water. The washed gel was then suspended in 25 ml DMF containing 55 mmoles tributylamine and 50 mmoles of the adduct of Example 21. The suspension was tumbled end-to-end for about 2 hours at room temperature. The product was washed with 250 ml DMF and then twice with 250 ml acetone per wash. The product gel was stored in acetone. To demonstrate the activation of the gel, covalent binding of a serum protein was attempted; it was determined that the gel was able to bind covalently 15 mg bovine serum albumin per ml gel. The activated gel (20 ml) was washed with 100 ml distilled water, then with 100 ml 0.1 M NaHC0 3 (pH 9). The washed gel was suspended in 100 ml 0.1 M NaHC0 3 (pH 9) containing 10% ethylene glycol. The suspension was tumbled end-over-end at room temperature for 24 hours. The gel was resuspended in 0.1 M NaOH and tumbled for 14-20 hours at room temperature. Finally, the gel " was washed sequentially with 100 ml each of distilled water, 1 M NaCl, distilled water and PBS. Example 23 Ligand Leakage Experiments The experiments were conducted by using I- 125 labeled BSA as the ligand coupled to DCTFP activated SEPHAROSE CL-4B as the activated carrier. After extensive washing to remove the unbound ligand as much as possible, the gel containing immobilized I- 125 labeled BSA was packed into a column (1X10 cm 2 ) and was equilibrated at room temperature with 0.01 M Tris, pH 9 containing 0.1 M ethanolamine. Immediately 10 ml column effluent was collected and the amount of 1-125 labeled BSA ligand was quantified. The column outlet was clamped and left at room temperature in the above- mentioned ethanolamine-Tris solution. After 24 hours, 10 ml of equilibrating solution was allowed to pass through the column and the eluate was measured and the amount of ligand leaked out of the gel was calculated. Less than 0.75% of the total immobilized 1-125 labeled BSA could be leaked out of the gel during any 24-hour incubation period. Example 24 Non-covalent Binding of Serum Proteins The gels of Examples 13-20 (0.5-1.0 ml) were mixed with 1-2 ml protein solution (20-40 mg protein/ml) in a test tube and tumbled end-to-end at room temperature for 5 minutes. After centrifugation, the supernatant was removed and the gel was washed twice with PBS. The amount of protein in the supernatant and washes was determined and was equated to the amount unbound. In some cases, additional washing steps were introduced. The results are shown in Table 2. TABLE 2 Serum Protein Bound (mg protein per ml gel) 0 5 0 5 a Bovine serum albumin and human serum albumin were dissolved in 0.05 M sodium bicarbonate, pH 8.5 0 'Ηuman serum IgG was dissolved in PBS. Example 25 " Enrichment of Specific Radioactivity of 1-125 Labeled Bovine Serum Albumin (BSA) by * Selective Adsorption on 2-Mercaptoethanol 5 Substituted SEPHAROSE CL-4B Gel Activated bv 3.5-Dichloro-2.4.6-trifluoropyridine (DCTFP) A quantity of 4 ml 1-125 labeled BSA having a specific activity of 1000 cpm per mg protein in a concentration of 20 mg/ml was added to 0.5 ml of 2- 10 mercaptoethanol substituted SEPHAROSE CL-4B gel activated by DCTFP at room temperature for 5 minutes. Then the gel was centrifuged briefly and the supernatant was removed. The gel was washed 3 times with 20 mM sodium phosphate, pH 7.5 before the 1-125 15 labeled BSA was eluted with two 4 ml portions of 0.1 M glycine-HCl, pH 2.8. The specific activity of the 1-125 labeled BSA was enriched to 3550 cpm per mg protein. Example 26 20 Enrichment of Specific Radioactivity of 1-125 LabeledHuman IgG bv Selective Adsorption on Ethylene Glycol Substituted SEPHAROSE CL-4B Gel Activated bv 3,5-Dichloro-2.4.6-trifluoropyridine (DCTFP) 25 The procedure of Examples 24 and 25 was followed using 1-125 labeled human IgG having a specific activity of 5,100 cpm per mg protein in a concentration of 20 mg/ml The " specific activity was * . enriched to 12,200 cpm per mg protein. 30 Example 27 Separation of IgG and Serum Albumin from Human Serum bv Chromatography on O-Gel 3 ml of the gel prepared in accordance with Example 15 was washed with about 10 ml of 20 mM sodium 35 phosphate, pH 7.4. 1 ml filtered human serum (diluted 1:100 in 20 mM phosphate buffer, pH 7.4) was passed through the column at room temperature at a flow rate of 1.25 ml per minute. The column was then washed with the same phosphate buffer. Bound proteins were eluted, first with 10 mM sodium phosphate containing 0.5 M K 2 S0 4 (pH 7.4), followed by 0.1 M glycine buffer at progressively lower pH values of 5.0, 4.0 and 2.8, all at the same flow rate previously indicated. Except for a first fraction comprising non-adsorbed proteins and having a volume of 60 ml, 1.5 ml fractions were collected for each wash and the OD at 280 nm for each fraction monitored continuously in a LKB 2238 UV Cord. Fractions were collected in an LKB 2070 Ultrorac fraction collector. The pH was monitored using an LKB 2195 pH/Ion Monitor. As illustrated in Figure 2, the diluted human serum gave a chromatogram with five protein fractions. Peak I contained any non-adsorbed proteins; based on absorbance at 280 nm, the unbound protein represented 8% of the total protein applied to the column. Peak II contained materials desorbed by 10 mM phosphate buffer, pH 7.4, containing 0.5 M K 2 S0 4 . This fraction contained most of the serum albumin, and accounted for 32% of the total protein. Peak III material was desorbed with 0.1 M glycine at pH 5.0; peak IV material, at pH 4.0; and peak V material, at pH 2.8. The peak III fraction contained most of the immunoglobulin G (with very minor amounts of contaminating serum albumin) ; the fraction accounted for 15% of the total protein applied. Immunoglobulins M and A were found in the fractions of peaks IV and V, respectively. The concentrations of serum albumin and various immunoglobulins in each fraction was determined using specific Sandwich ELISA. Figure 3 illustrates the specific sandwich ELISA patterns of the serum after chromatography under the conditions specified for Fig. 2. The legends identify the protein for which each ELISA is specific. The identity of the various proteins was further confirmed by 10-15% gradient SDS polyacrylamide gel electrophoresis (PAGE) under reducing conditions. The developed gel as depicted in Fig. 4 comprises 7 lanes: lane 1, for molecular weight marker reference proteins; lane 2, for unfractionated human serum; and lanes 3-7, for fractions I-V of Fig. 2, respectively. Similar chromatographic patterns were observed for rabbit and mouse sera (Figs. 5A and 5B, respectively) . Identification of the major proteins in each peak fraction of the rabbit and mouse sera by PAGE (Figs. 6A and 6B, respectively) was also consistent with the separation observed with human sera. In addition, similar chromatographic patterns were observed when the 0.5 M K 2 S0 4 wash solution was replaced with phosphate buffer saline (PBS) . In the latter instance, however, the level of albumin contamination in the IgG fraction was higher. The chromatograms of human, rabbit and mouse sera, as well as the immunological and electrophoretic analyses of peak protein fractions, all illustrate the extraordinary selectivity and protein biding capacity of the gel for serum albumin and for various immunoglobulins. It is particularly worth noting that none of the commercially available immobilized Staphylococcus Protein A gels bind IgG from rat sera; however, the inventive gel has been shown to be as effective with rat sera as with that of other species tested. Example 28 Separation of Bovine Serum Albumin and IgG Fifteen ml solution containing a mixture of 7.5 mg bovine serum albumin and 7.5 mg bovine immunoglobulin G in 20 mM sodium phosphate buffer, pH 7.5 was applied on a column of O-gel (1 ml) at a flow rate of 0.5 ml per minute. Fractions of 2 ml were collected. After washing the column with approximately 10 ml 20 mM sodium phosphate buffer, pH 7.5 serum albumin was eluted with 10 mM sodium phosphate, pH 7.4 and containing 150 mM NaCl. Subsequent to the elution of serum albumin, the immunoglobulin was eluted by using 0.1 M glycine, pH 4. The completeness of the separation can be seen in the electrophoretogram of Figure 7, wherein: column (1) comprises molecular weight markers; column (2) is an albumin sample; column (3) is an IgG sample; column (4) is the unbound, flow-through fraction; columns (5) and (6) are fractions eluted with 20 mM sodium phosphate, pH 7.4 containing 150 mM NaCl ( containing albumin) ; and columns (7) and (8) are fractions eluted with 0.1 M glycine, pH 4 (containing IgG) . Example 29 Separation of Chicken Serum Albumin and IgG Fifteen ml solution containing a mixture of 7.5 mg chicken serum albumin and 7.5 mg chicken immunoglobulin G in 20 mM sodium phosphate buffer, pH 7.5 was applied on a column of O-gel (2 ml) at a flow rate of 0.5 ml per minute. Fractions of 2 ml were collected. After washing the column with approximately 10 ml 20 mM sodium phosphate buffer, pH 7.5 serum albumin was eluted with 10 mM sodium phosphate, pH 7.4 and containing 150 mM NaCl. Subsequent to the elution of serum albumin, the immunoglobulin was eluted by using 0.1 M glycine, pH 4. The completeness of the separation can be seen in the electrophoretogram of Figure 8, wherein: column (1) comprises molecular weight markers; column (2) is -t an albumin sample; column (3) is an IgG sample; column 5 (4) is the unbound, flow-through fraction; columns (5) and (6) are fractions eluted with 20 mM sodium phosphate, pH 7.4 containing 150 mM NaCl (containing albumin) ; and columns (7) and (8) are fractions eluted with 0.1 M glycine, pH 4 (containing IgG). 10 Example 30 Separation of Goat Serum Albumin and IgG Fifteen ml solution containing a mixture of 7.5 mg goat serum albumin and 7.5 mg goat immunoglobulin G in 20 mM sodium phosphate buffer, pH 15 7.5 was applied on a column of O-gel (2 ml) at a flow rate of 0.5 ml per minute. Fractions of 2 ml were collected. After washing the column with approximately 10 ml 20 mM sodium phosphate buffer, pH 7.5 serum albumin was eluted with 10 mM sodium 20 phosphate, pH 7.4 and containing 150 mM NaCl. Subsequent to the elution of serum albumin, the immunoglobulin was eluted by using 0.1 M glycine, pH 4. The completeness of the separation can be seen in the electrophoretogram of Figure 9, wherein: column 25 (1) comprises molecular weight markers; column (2) is an albumin sample; column (3) is an IgG sample; column (4) is the unbound, flow-through fraction; columns (5) and (6) are fractions eluted with 20 mM sodium phosphate, pH 7.4 containing 150 mM NaCl (containing 30 albumin) ; and columns (7) and (8) are fractions eluted with 0.1 M glycine, pH 4 (containing IgG). Example 31 Separation of Mouse Serum Albumin and IgG Fifteen ml solution containing a mixture of 35 7.5 mg mouse serum albumin and 7.5 mg mouse immunoglobulin G in 20 mM sodium phosphate buffer, pH 7.5 was applied on a column of O-gel (2 ml) at a flow rate of 0.5 ml per minute. Fractions of 2 ml were collected. After washing the column with approximately 10 ml 20 mM sodium phosphate buffer, pH 7.5 serum albumin was eluted with 10 mM sodium phosphate, pH 7.4 and containing 150 mM NaCl. Subsequent to the elution of serum albumin, the immunoglobulin was eluted by using 0.1 M glycine, pH 4. The completeness of the separation can be seen in the electrophoretogram of Figure 10, wherein: column (1) comprises molecular weight markers; column (2) is an albumin sample; column (3) is an IgG sample; column (4) is the unbound, flow-through fraction; columns (5) and (6) are fractions eluted with 20 mM sodium phosphate, pH 7.4 containing 150 mM NaCl (containing albumin) ; and columns (7) and (8) are fractions eluted with 0.1 M glycine, pH 4 (containing IgG). Example 32 Separation of Pig Serum Albumin and IgG Fifteen ml solution containing a mixture of 7.5 mg pig serum albumin and 7.5 mg pig immunoglobulin G in 20 mM sodium phosphate buffer, pH 7.5 was applied on a column of O-gel (2 ml) at a flow rate of 0.5 ml per minute. Fractions of 2 ml were collected. After washing the column with approximately 10 ml 20 mM sodium phosphate buffer, pH 7.5 serum albumin was eluted with 10 mM sodium phospriate, pH 7.4 and containing 150 mM NaCl. Subsequent to the elution of serum albumin, the immunoglobulin was eluted by using 0.1 M glycine, pH 4. The completeness of the separation can be seen in the electrophoretogram of Figure 11, wherein: column (1) comprises molecular weight markers; column (2) is an albumin sample; column (3) is an IgG sample; column (4) is the unbound, flow-through fraction; columns (5) and (6) are fractions eluted with 20 mM sodium phosphate, pH 7.4 containing 150 mM NaCl (containing albumin); and i, columns (7) and (8) are fractions eluted with 0.1 M 5 glycine, pH 4 (containing IgG) . Example 33 Separation of Rabbit Serum Albumin and IgG Fifteen ml solution containing a mixture of 7.5 mg rabbit serum albumin and 7.5 mg rabbit 10 immunoglobulin G in 20 mM sodium phosphate buffer, pH 7.5 was applied on a column of O-gel (2 ml) at a flow rate of 0.5 ml per minute. Fractions of 2 ml were collected. After washing the column with approximately 10 ml 20 mM sodium phosphate buffer, pH 15 7.5 serum albumin was eluted with 10 mM sodium phosphate, pH 7.4 and containing 150 mM NaCl. Subsequent to the elution of serum albumin, the immunoglobulin was eluted by using 0.1 M glycine, pH 4. The completeness of the separation can be seen in 20 the electrophoretogram of Figure 12, wherein: column (1) comprises molecular weight markers; column (2) is an albumin sample; column (3) is an IgG sample; column (4) is the unbound, flow-through fraction; columns (5) and (6) are fractions eluted with 20 mM sodium 25 phosphate, pH 7.4 containing 150 mM NaCl (containing albumin) ; and columns (7) and (8) are fractions eluted with 0.1 M glycine, pH 4 (containing IgG). Example 34 » * Separation of Rat Serum Albumin and IgG 30 Fifteen ml solution containing a mixture of , 7.5 mg rat serum albumin and 7.5 mg rat immunoglobulin G in 20 mM sodium phosphate buffer, pH 7.5 was applied on a column of O-gel (2 ml) at a flow rate of 0.5 ml per minute. Fractions of 2 ml were collected. After 35 washing the column with approximately 10 ml 20 mM sodium phosphate buffer, pH 7.5 serum albumin was eluted with 10 mM sodium phosphate, pH 7.4 and containing 150 mM NaCl. Subsequent to the elution of serum albumin, the immunoglobulin was eluted by using 0.1 M glycine, pH 4. The completeness of the separation can be seen in the electrophoretogram of Figure 13, wherein: column (1) comprises molecular weight markers; column (2) is an albumin sample; column (3) is an IgG sample; column (4) is the unbound, flow-through fraction; columns (5) and (6) are fractions eluted with 20 mM sodium phosphate, pH 7.4 containing 150 mM NaCl (containing albumin); and columns (7) and (8) are fractions eluted with 0.1 M glycine, pH 4 (containing IgG) . Example 35 Non-covalent binding of Non-serum Proteins The gel of Example 15 (0.5 ml) was mixed with 3 ml protein solution (approximately 1 mg protein per ml) in a test tube and tumbled end-to-end for 15 minutes. After centrifugation, the supernatant was removed and the gel washed three times with 3 ml buffer per wash. The amount of protein in the supernatant and washes was determined and equated with the amount unbound. The results are shown in Table 3. Table 3 Non-Covalent Binding of Non-Serum Proteins to O-Gel Protein Protein Amount of Protein Dissolved In Bound to 1 ml Gel (mg/ml gel) *P: 20 mM sodium phosphate, pH 7.4 **A: 10% Ammonium sulfate solution. Example 36 Fractionation of Human Serum Proteins Using Ethylene Glvcol Substituted Gel Prepared via Reaction Product of DMAP-DCTFP Adduct with Sepharose CL-4B The ethylene glycol substituted gel of Example 22 (7 ml) was packed in a column and washed with 20 mM sodium phosphate (pH 7.4). One ml human serum diluted with the same phosphate buffer was applied to the column at a flow rate of 1.25 ml per minute. The column was sequentially washed with the phosphate buffer, phosphate buffer containing 0.5 M K 2 S0 4 , and 0.1 M glycine (pH 5, 4 and 2.8). 3 ml fractions were collected and absorbance at 280 nm recorded. Four major fractions were obtained: serum albumin was collected in the first fraction peak, while immunoglobulins and other serum proteins were collected in the subsequent three fractions. Example 37 Fractionation of Non-Human Serum Proteins Following the general procedure described in Example 36, various non-human serum samples were also successfully fractionated using substituted gels prepared in accordance with the present invention. The serum samples and DCTFP-DMAP activated gel treatment agents (i.e., ligands) employed are reported in Table 3; the corresponding chromatograms for the samples identified in Table 4 " are illustrated in Figures 14-17. In each instance, the column containing the indicated gel was sequentially washed after introduction of the serum sample with the phosphate buffer, phosphate buffer containing 0.5 M K 2 S0 4 , 0.1 M glycine at pH 4.5 and 0.1 M glycine at pH 2.8. TABLE 4 Fractionation of Non-Human Sera Species Ligand Chromatogram Figure- 5 Goat Hydroxide (NaOH treated)14 Mouse Glycinelδ Rabbit Glycine16 Rabbit Ethylene Diaminel7 10 Example 38 Affinity Chromatography and Purification of Human IgG Immobilized Protein A gel (1 ml) prepared according to the procedure of Example 12 was packed 15 into a small column (0.8 X 2.3 cm 2 ). Human serum (3 ml) diluted with 2 volumes (6 ml) PBS, pH 7.4 was applied to the column. The column was washed with 20 ml PBS and the bound IgG was eluted with 5 ml 0.1 M sodium acetate, pH 3.5. The results are shown in Fig 20 18. A quantity of 14.7 mg human IgG was isolated per milliliter of gel. From the foregoing description, one skilled in the art can readily ascertain the essential characteristics of the invention and, without 25 departing from the spirit and scope thereof, can adapt the invention to various usages and conditions. Changes in form and substitution of equivalents are contemplated as circumstances " may suggest or render * expedient, and although specific terms have been 30 employed herein, they are intended in a descriptive ι sense and not for purposes of limitation.

Claims: CLAIMS 1. A method for preparing a modified polymer comprising: reacting a polymer containing at least one nucleophilic group under basic conditions with a substituted 2-halopyridine of the formula: wherein X is F, Cl or Br; Y is F, Cl, Br, N0 2 , CH 3 or CF 3 ; and n is 1 to 4; and wherein, when n is greater than 1, the substituents designated by Y may be the same or different, at least one of said substituents being an electron withdrawing group, thereby preparing a product wherein at least some of the nucleophilic groups of the polymer have been modified by reaction with said 2-halopyridine. 2. A method according to claim 1, wherein said polymer is selected from cellulose, agarose, dextran and cross-linked products thereof. 3. A method according to claim 1, wherein said polymer is selected from poly(ethylene glycol), poly(vinyl alcohol) , poly(hydroxyethyl methacrylate) and nylon. 4. A method according to any one of claims 1 to 3, wherein said polymer is in a solid form selected from gels, beads, fibers, fabrics and membranes. 5. A method according to any one of claims 1 to 4, wherein the substituted 2-halopyridine is selected from pentafluoropyridine; 3,5-dichloro-2,4,6- trifluoropyridme; 3,5-dinitro-2-chloropyridine; 2,3,5-trichloropyridine; 2,6-difluoropyridine; 2- chloro-5-trifluoromethylpyridme; 2,3,5,6-tetrafluoro- 4-methylpyridine; and 2,3,5,6-tetrafluoropyridine. 6. A method according to any one of claims 1 to 5, wherein the basic conditions comprise an excess of a tertiary amine in a polar organic solvent. 7. A method according to claim 6, wherein said tertiary amine is triethylamine, tributylamine or 4- dimethylaminopyridine. 8. A method according to claim 1, further comprising reacting said modified polymer with an organic ligand that contains at least one substituent selected from primary amino groups, secondary amino groups, primary hydroxyl groups, secondary hydroxyl groups and sulfhydryl groups. 9. A method according to claim 8, wherein the modified polymer has a stru to general formula 1(a) or 1(b wherein A is o, S or NR, gen or optionally substituted alkyl, aryl or aralkyl; each X is independently selected from the group consisting of halogen, trihalomethyl and nitro; each Y is independently selected from the group consisting of halogen, hydroxyl, amino and -A 1 R 4 , in which A 1 is 0, S or NR j , R 4 is optionally substituted alkyl, aryl, or aralkyl, and R g is hydrogen or optionally substituted alkyl, aryl or aralkyl, with the proviso that at least one Y in Formula 1(a) or Y in Formula 1(b) is not halogen; each of X 1 is hydrogen or optionally substituted alkyl, aryl or aralkyl; at least one Y, is hydrogen and the other is hydrogen or optionally substituted alkyl, aryl or aralkyl; R-, is hydrogen, optionally substituted alkyl, aryl or aralkyl, or -NR 2 R 3 , in which R 2 and R 3 are the same or different and are optionally substituted alkyl, aryl or aralkyl; and 1- is a polymer. 10. A method according to claim 9, wherein Y is selected from hydroxyl, amino and -A,R 4 , in which A, is 0, S or NR g , R 4 is optionally substituted alkyl, aryl, or aralkyl, and R g is hydrogen or optionally substituted alkyl, aryl or aralkyl. 11. A method according to claim 9, wherein Y is selected from hydroxyl, -SCH 2 CH 2 OH, -0CH 2 CH 2 0H, - NHCH 2 C00H, -SCH 2 CH 2 COOH, -NHCH ( COOH) CH 2 CH 2 COOH , -SCH 2 CHOHCHOHCH 2 SH , -SCH 2 CHOHCHOHCH 2 SCH 2 CONH 2 , -NHCH 2 CH 2 NH 2 and -NHCH 2 CH 2 OH . 12. A method according to claim 9, wherein X is Cl or F. 13. A method according to claim 9 , wherein R. is -N(CH 3 ) 2 . 14. A method according to claim 9, wherein A is 0. 15. A method according to claim 9, which comprises A. reacting together (a) a halogen-substituted pyridine of general formula II: wherein each X 2 is independently selected from the group consisting of halogen, trihalomethyl and N0 2 ; at least one Y 2 is halogen and the other Y 2 is selected from the group consisting of halogen and -A 1 R 4 , in which A 1 is O, S or NR g , R 4 is optionally substituted alkyl, aryl, or aralkyl, and R g is optionally substituted alkyl, aryl or aralkyl; and Z 2 is a suitable leaving group; (b) a pyridine base of general formula III: wherein each of X 1 is hydrogen or optionally substituted alkyl, aryl or aralkyl; at least one Y, is hydrogen and the other Y 1 is hydrogen or optionally substituted alkyl, aryl or aralkyl; and R 1 is hydrogen, optionally- substituted alkyl, aryl or aralkyl, or -NR 2 R 3 -in which R 2 and R 3 are the same or different and are optionally-substituted alkyl, aryl or aralkyl, and (c) a nucleophile-containing polymer, at a temperature in the range of about 0° to about 90° over a period of time of about 10 minutes to about 20 hours in an organic solvent to form a compound of general formula IV(a) or IV(b) I ~A N wherein the substituents are as previously defined, and where both Y 2 in Formula IV(a) are halogen or Y 2 in Formula IV(b) is halogen, further reacting said compound of general formula IV(a) or IV(b) with hydroxide ions or a compound of general formula VI: R 6 - B - R 7 wherein B is an optionally-substituted alkyl, aryl or aralkyl moiety of 2 to about 10 carbon atoms; and each of R 6 and R 7 is -OH, -SH or -NR g R,, in which each of R g and R-, is hydrogen or optionally-substituted alkyl, aryl or aralkyl, at a temperature of about 0° to about 100° C for about 10 minutes to about 20 hours in a suitable solvent; or B. (1) reacting the group consisting of halogen, trihalomethyl and N0 2 ; at least one Y 2 is halogen and the other Y 2 is selected from the group consisting of halogen, hydroxyl, amino and -A 1 R 4 , in which A 1 is O, S or NR j , R 4 is optionally substituted alkyl, aryl, or aralkyl, and R j is hydrogen or optionally substituted alkyl, aryl or aralkyl; and Z 2 is a suitable leaving group, with (b) a pyridine base of general formula III: wherein each of X 1 is hydrogen or optionally substituted alkyl, aryl or aralkyl; at least one Y 1 is hydrogen and the other Y., is hydrogen or optionally substituted alkyl, aryl or aralkyl; and R, is hydrogen, optionally-substituted alkyl, aryl or aralkyl, or -NR 2 R 3 in which R 2 and R 3 are the same or different and are optionally-substituted alkyl, aryl or aralkyl, at a temperature in the range of about 0° to about 90° over a period of time of about 10 minutes to about 20 hours in an organic solvent to form an intermediate of general formula V wherein Z is a suitable counterion; and (2) reacting said intermediate of general formula V with (c) a nucleophile containing polymer, under basic conditions in a suitable organic solvent or IV(b) defined, and where both Y 2 in Formula IV(a) are halogen or Y 2 in Formula IV(b) is halogen, further reacting said compound of general formula IV(a) or IV(b) with hydroxide ions or a compound of general formula VI: R 6 - B - R 7 wherein B is an optionally-substituted alkyl, aryl or aralkyl moiety of 2 to about 10 carbon atoms; and each of R 6 and R 7 is -OH, -SH or -NR g p , in which each of R g and R 9 is hydrogen or optionally-substituted alkyl, aryl or aralkyl, at a temperature of about 0° to about 100° C for about 10 minutes to about 20 hours in a suitable solvent. 16. A method according to claim 15, wherein said halogen-substituted pyridine is selected from 3,5- dichloro-2 ,4,6-trifluoropyridine, pentafluoropyridine and pentachloropyridine. 17. A method according to claim 15, wherein said pyridine base is 4-dimethylaminopyridine. 18. A method according to claim 15, wherein - A,,R 4 in general formula II is selected from -SCH 2 CH 2 OH, -OCH 2 CH 2 OH , -NHCH 2 CH 2 OH, -NHCH 2 COOH , -SCH 2 CH 2 COOH, -NHCH ( COOH) CH 2 CH 2 COOH , -SCH 2 CHOHCHOHCH 2 SH , -SCH 2 CHOHCHOHCH 2 SCH 2 CONH 2 , -NHCH 2 CH 2 NH 2 and -NHCH 2 CH 2 OH . 19. A modified polymer comprising the reaction product of a polymer containing at least one nucleophilic group under basic conditions with a substituted 2-halopyridine of the formula: wherein X is F, Cl or Br; Y is F, Cl, Br, N02, CH 3 or CF 3 ; and n is 1 to 4; and wherein, when n is greater than 1, the substituents designated by Y may be the same or different, at least one of said substituents being an electron withdrawing group, thereby preparing a product wherein at least some of the nucleophilic groups of the polymer have been modified by reaction with said 2-halopyridine. 60 20. A modified polymer according to claim 19, wherein the modified polymer has a structure corresponding to general formula 1(a) or 1(b): wherein A is 0, S or NR, in which R is hydrogen or optionally substituted alkyl, aryl or aralkyl; each X is independently selected from the group consisting of halogen, trihalomethyl and nitro; each Y is independently selected from the group consisting of halogen, hydroxyl, amino and -A 1 R 4 , in which A 1 is 0, S or NR j , R 4 is optionally substituted alkyl, aryl, or aralkyl, and R g is hydrogen or optionally substituted alkyl, aryl or aralkyl, with the proviso that at least one Y in Formula 1(a) or Y in Formula 1(b) is not halogen; and each of X, is hydrogen or optionally substituted alkyl, aryl or aralkyl; at least one Y, is hydrogen and the other is hydrogen or optionally substituted alkyl, aryl or aralkyl; R, is hydrogen, optionally substituted alkyl, aryl or aralkyl, or -NR 2 R 3 , in which R 2 and R 3 are the same or different and are optionally substituted alkyl, aryl or aralkyl; and |- is a polymer. 21. A modified polymer according to claim 20, wherein Y is selected from hydroxyl, amino and -A,R 4 , in which A, is 0, S or NR j , R 4 is optionally substituted alkyl, aryl, or aralkyl, and R g is hydrogen or optionally substituted alkyl, aryl or aralkyl. 22. A method of covalently binding an organic ligand to a polymer, comprising: (1) forming a modified polymer in accordance with any one of claims 1-7; and (2) reacting said modified polymer directly with said organic ligand. 23. A method for recovering at least one organic material from a composition comprising same by affinity chromatography, which comprises (1) contacting said organic material in a suitable buffer solution with a modified polymer according to claim 21, thereby forming a bound complex; and (2) separating unbound components of said composition from said bound complex. 24. A method according to claim 23, wherein said organic material is a biologically active ligand selected from the group consisting of proteins, enzymes, antibodies, antigens, amino acids, nucleic acids, thiol compounds, cofactors, haptens and hormones. 25. A method according to claim 24, wherein said buffer is selected from the group consisting of 0.02 M sodium phosphate (pH 7.5), 0.15 M NaCl in 0.02 M to 0.05 M sodium phosphate (pH 7.4) and 0.05 M sodium bicarbonate (pH 8.5). 26. A method according to claim 24, further comprising (3) separating said organic material from said complex. 27. A method according to claim 24, wherein said organic material is an immunoglobulin. 28. A method according to claim 27, wherein said immunoglobulin is IgG selected from the group consisting of human, bovine, chicken, goat, mouse, pig, rabbit and rat IgG. 29. A method according to claim 26, wherein said organic material is serum albumin. 30. A method according to claim 29, wherein said serum albumin is selected from the group consisting of human, bovine, chicken, goat, mouse, pig, rabbit and rat serum albumin. 31. A method according to claim 23, wherein said composition comprises whole serum. 32. A method according to claim 23, wherein said contacting is carried out in a chromatography column, and further comprising recovering said organic material in substantially purified form by elution from said chromatography column.

Inventors: NGO THAT T, NGO, THAT, T.
Applicants: BIOPROBE INT INC, BIOPROBE INTERNATIONAL, INC.
Application year: 1989
Main classification: C12N11
IPC codes: A61K39, B01D15, B01J20, C07K1, C07K14, C07K16, C08B37, C08F8, C08G65, C08G69, C12N9, C12N11, G01N30, G01N33